Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 24
- Registration Number
- NCT06743581
- Locations
- 🇨🇦
Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT06731270
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT06699602
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 152
- Registration Number
- NCT06656598
- Locations
- 🇫🇷
Caen - CHU, Caen, France
🇫🇷Caen - CRLCC, Caen, France
🇫🇷Créteil - CHI, Créteil, France
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06651593
- Locations
- 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 112
- Registration Number
- NCT06623656
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 378
- Registration Number
- NCT06616584
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT06594991
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Stanford University (Data Collection Only), Stanford, California, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 369
- Registration Number
- NCT06585410
A Study of Gemcitabine/Cisplatin Plus Cemiplimab (REGN2810, Anti-PD-1) With or Without Fianlimab (REGN3767, Anti-LAG-3) in Patients With Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 36
- Registration Number
- NCT06571708
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.